Open-house discount agreements for the original apixaban medicine 2026-11

Summary

The tender concerns the conclusion of discount agreements for an original medicinal product containing apixaban under an open-house procedure. Suitable pharmaceutical companies may participate throughout the contract period; no individual negotiations will be held, and uniform contract terms will apply to all participants. The contract will run for up to 24 months from 1 October 2026 and will end no later than 30 September 2028, or earlier if the patent or market exclusivity expires. The submission deadline is 29 September 2028. The precise participation, exclusion, qualification and compliance requirements must be checked in the tender documents.